ACCOLADE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.61 USD | +1.69% |
|
+0.84% | -69.94% |
| Jun. 28 | Sector Update: Health Care Stocks Decline in Late Afternoon Trading | MT |
| Jun. 28 | Sector Update: Health Care | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company shows low valuation levels, with an enterprise value at 0.26 times its sales.
- The company appears to be poorly valued given its net asset value.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -69.94% | 289M | C- | ||
| +18.33% | 83.89B | C+ | ||
| -28.29% | 71.08B | B- | ||
| +0.99% | 26.77B | C+ | ||
| +3.67% | 17.74B | A- | ||
| -9.99% | 17.24B | B | ||
| +1.86% | 15.6B | A- | ||
| +79.98% | 13.84B | C- | ||
| -25.09% | 12.92B | - | - | |
| +74.41% | 12.87B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ACCD Stock
- Ratings Accolade, Inc.
